Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-α-converting enzyme

Analytical Biochemistry

Volumn 372, Issue 1, 2008, Pages 1-10

  Sagi, Irit ^a   Milla, Marcos E ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH;

CONVERTING ENZYME; ENZYMATIC MECHANISMS; TUMOR NECROSIS FACTOR ALPHA;

STRUCTURAL DYNAMICS;

COMPLEMENTARY DNA; ENZYME PRECURSOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

AUTOIMMUNE DISEASE; CATALYSIS; CROHN DISEASE; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; MACROPHAGE; MOLECULAR CLONING; MONOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

EID: 36048966063     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.07.037     Document Type: Review

References (83)

1. McGeehan G.M., Becherer J.D., Bast Jr. R.C., Boyer C.M., Champion B., Connolly K.M., et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370 (1994) 558-561
2. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S.S., et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370 (1994) 218-220
3. Gearing A.J.H., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370 (1994) 555-557
4. Moss M.L., Jin C., Milla M.E., Bickett D.M., Buckhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-α. Nature 385 (1997) 733-736
5. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., and Wolfson M.F. A metalloproteinase disintegrin that releases tumour necrosis factor-α from cells. Nature 385 (1997) 729-733
6. Old L.J. Tumor necrosis factor. Science 230 (1985) 630-632
7. Beutler B., and Cerami A. Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Annu. Rev. Biochem. 57 (1988) 505-518
8. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., and Milsark I.W. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470-474
9. Piguet P.F., Grau G.E., Allet B., and Vasalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166 (1987) 1280-1289
10. Peterson P.K., Gekker G., Chao C.C., Hu S., Edelman C., Balfour Jr. H.H., and Verhof J. Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-α-mediated mechanism. J. Clin. Invest. 89 (1992) 574-580
11. Williams R.O., Feldmann M., and Maini R. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89 (1992) 9784-9788
12. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnaborg S.W., Lee D.C., et al. An essential role for ectodomain shedding in mammalian development. Science 282 (1998) 1279-1280
13. Huovila A.-P.J., Turner A.J., Pelto-Huikko M., Karkainen I., and Ortiz R.M. Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 30 (2005) 413-422
14. Blobel C.P. ADAMs: Key components in EGFR signaling and development. Nat. Rev. Mol. Biol. 15 (2005) 598-606
15. Arribas J., and Borroto A. Protein ectodomain shedding. Chem. Rev. 102 (2002) 4627-4638
16. Moss M.L., and Bartsch J.W. Therapeutic benefits from targeting of ADAM family members. Biochemistry 43 (2004) 7227-7235
17. Blobel C.P. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflammation Res. 51 (2002) 83-84
18. Wolfsberg T.G., Primakoff P., Myles D.G., and White J.M. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: Multipotential functions in cell-cell and cell-matrix interactions. J. Cell. Biol. 131 (1995) 275-278
19. Wolfsberg T.G., Straight P.D., Gerena R.L., Huovila A.P., Primakoff P., Myles D.G., et al. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloproteinase domain. Dev. Biol. 69 (1995) 378-383
20. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science 291 (2001) 1304-1351
21. White J.M. ADAMs: Modulators of cell-cell and cell-matrix interactions. Curr. Opin. Cell Biol. 15 (2003) 598-606
22. Schlondorff J., and Blobel C.P. Metalloprotease disintegrins: Modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J. Cell Sci. 112 (1999) 3603-3617
23. Killar L., White J., Black R., and Peschon J. Adamalysins: A family of metzincins including the TNF-α converting enzyme (TACE). Ann. N.Y. Acad. Sci. 30 (1999) 442-452
24. Moss M.L., Becherer J.D., Milla M.E., Pahel G., Lambert M., Andrews R., et al. TNF-α convertase. In: Bottomley K.M.K., Bradshaw D., and Nixon J.S. (Eds). Metalloproteinases as Targets for Anti-inflammatory Drugs (1999), Birkhauser, Basel, Switzerland
25. Massova I., Kotra L.P., Fridman R., and Mobashery S. Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J. 12 (1998) 1075-1095
26. Becherer J.D., and Blobel C.P. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr. Top. Dev. Biol. 54 (2003) 101-123
27. Milla M.E., Gonzales P.E., and Leonard J.D. The TACE zymogen. Cell Biochem. Biophys. 44 (2006) 342-348
28. Fahrenholz F., and Postina R. α-Secretase activation: An approach to Alzheimer's disease therapy. Neurodegenerative Dis. 3 (2006) 255-261
29. Gonzales P.E., Solomon A., Miller A.B., Leesnitzer M.A., Sagi I., Milla M.E., et al. Inhibition of the tumor necrosis factor-α-converting enzyme by its prodomain. J. Biol. Chem. 279 (2004) 31638-31645
30. Solomon A., Rosenblum G., Gonzales P.E., Leonard J.D., Mobashery S., Milla M.E., et al. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-α-converting enzyme and matrix metalloproteinases despite their high structural similarity. J. Biol. Chem. 279 (2004) 31646-31654
31. Leonard J.D., Lin F., and Milla M.E. Chaperone-like properties of the prodomain of TACE and the functional role of its cysteine switch. Biochem. J. 387 (2005) 797-805
32. Milla M.E., Leesnitzer M.A., Moss M.L., Clay W.C., Carter H.L., Miller A.B., et al. Specific sequence determinants are required for the expression of functional tumor necrosis factor-α converting enzyme (TACE). J. Biol. Chem. 274 (1999) 30563-30570
33. Roghani M., Becherer J.D., Moss M.L., Atherton R.E., Erdjument-Bromage H., Arribas J., et al. Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic activity. J. Biol. Chem. 274 (1999) 3531-3540
34. Anders A., Gilbert S., Garten W., Postina R., and Fahrenholz F. Regulation of the α-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 15 (2001) 1837-1839
35. Loechel F., Overgaard M.T., Oxvig C., Albrechtsen R., and Wewer U.M. Regulation of human ADAM 12 protease by the prodomain: Evidence for a functional cysteine switch. J. Biol. Chem. 274 (1999) 13427-13433
36. Sundberg C., Thodeti C.K., Kveiborg M., Larsson C., Parker P., Albrechtsen R., et al. Regulation of ADAM12 cell-surface expression by PKC epsilon. J. Biol. Chem. 279 (2004) 51601-51611
37. Wewer U.M., Morgelin M., Holck P., Jacobsen J., Lydolph M.C., and Johnsen A.H. ADAM12 is a four-leafed clover: The excised prodomain remains bound to the mature enzyme. J. Biol. Chem. 281 (2006) 9418-9422
38. Kang T., Zhao Y.G., Pei D., Sucic J.F., and Sang Q.X.A. Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites. J. Biol. Chem. 277 (2002) 25583-25591
39. Howard L., Maciewicz R.A., and Blobel C.P. Cloning and characterization of ADAM28: Evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochemical J. 348 (2000) 21-27
40. Borroto A., Ruiz-Paz S., de la Torre T.V., Borrell-Pages M., Merlos-Suarez A., Pandiella A., et al. Impaired trafficking and activation of tumor necrosis factor-α-converting enzyme in cell mutants defective in protein ectodomain shedding. J. Biol. Chem. 278 (2003) 25933-25939
41. Van Wart H.E., and Birkedal-Hansen H. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 87 (1990) 5578-5582
42. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378 (1997) 151-160
43. Springman E.B., Angleton E.L., Birkedal-Hansen H., and Van Wart H.E. Multiple modes of activation of latent human fibroblast collagenase: Evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc. Natl. Acad. Sci. USA 87 (1990) 364-368
44. Chen L.C., Noelken M.E., and Nagase H. Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1). Biochemistry 32 (1993) 10289-10295
45. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., et al. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. Science 284 (1999) 1667-1670
46. Baker D., Sohl J.L., and Agard D.A. A protein folding reaction under kinetic control. Nature 356 (1992) 263-265
47. Cunningham E.L., Jaswal S.S., Sohl J.L., and Agard D.A. Kinetic stability as a mechanism for protease longevity. Proc. Natl. Acad. Sci. USA 96 (1999) 11008-11014
48. Strausberg S., Alexander P., Wang L., Schwarz F., and Bryan P. Catalysis of a protein folding reaction: Thermodynamic and kinetic analysis of subtilisin BPN' interactions with its propeptide fragment. Biochemistry 32 (1993) 8112-8119
49. Eder J., Rheinnecker M., and Fersht A.R. Folding of subtilisin BPN': Characterization of a folding intermediate. Biochemistry 32 (1993) 18-26
50. Gallagher T., Gilliland G., Wang L., and Bryan P. The prosegment-subtilisin BPN' complex: Crystal structure of a specific "foldase,". Structure 3 (1995) 907-914
51. Bryan P., Wang L., Hoskins J., Ruvinov S., Strausberg S., Alexander P., et al. Catalysis of a protein folding reaction: Mechanistic implications of the 2.0 Å structure of the subtilisin-prodomain complex. Biochemistry 34 (1995) 10310-10318
52. Strange R.W., and Hasnain S.S. Combined use of XAFS and crystallography for studying protein-ligand interactions in metalloproteins. Methods Mol. Biol. 305 (2005) 167-196
53. Hodgson J. Remodeling MMPIs. Bio/Technology 13 (1995) 554-557
54. Docherty A.J., Crabbe T., O'Connell J.P., and Groom C.R. Proteases as drug targets. Biochem. Soc. Symp. 70 (2003) 147-161
55. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435 (1998) 39-44
56. Maskos K., Fernandez-Catalan C., Huber R., Bourenkov G.P., Bartunik H., Ellestad G.A., et al. Crystal structure of the catalytic domain of human tumor necrosis factor-α converting enzyme. Proc. Natl. Acad. Sci. USA 95 (1998) 3408-3412
57. Benkovic S.J., and Hammes-Schiffer S. A perspective on enzyme catalysis. Science 301 (2003) 1196-1202
58. Christianson D.W., and Lipscomb W.N. Carboxypeptidase-A, Acc. Chem. Res. 22 (1989) 62-69
59. Kilshtain-Vardi A., Shoham G., and Goldblum A. Mechanism of action of zinc proteinases: A MNDO/d/H study of alternative general-acid general-base catalytic pathways for carboxypeptidase-A. Intl. J.Q. Chem. 88 (2002) 87-98
60. Kotra L.P., Cross J.B., Shimura Y., Fridman R., Schlegel H.B., and Mobashery S. Insight into the complex and dynamic process of activation of matrix metalloproteinases. J. Am. Chem. Soc. 123 (2001) 3108-3113
61. Pelmenschikov V., and Siegbahn P.E. Catalytic mechanism of matrix metalloproteinases: Two-layered ONIOM study. Inorg. Chem. 41 (2002) 5659-5666
62. Bertini I., Calderone V., Fragai M., Luchinat C., Maletta M., and Yeo K.J. Snapshots of the reaction mechanism of matrix metalloproteinases. Angew. Chem. Intl. Ed. Engl. 45 (2006) 7952-7955
63. Kleifeld O., Frenkel A., Martin J.M.L., and Sagi I. Active site electronic and structure and dynamics during metalloenzyme catalysis. Nat. Struct. Biol. 10 (2003) 98-102
64. Solomon A., Akabayov B., Frenkel A., Milla M.E., and Sagi I. The TNFα converting enzyme recognizes and hydrolyzes peptides via distinct active site electronics and catalytic intermediates. Proc. Natl. Acad. Sci. USA 104 (2007) 4931-4936
65. Xue C.B., He X., Corbett R.L., Roderick J., Wasserman Z.R., Liu R.Q., et al. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1′, a series of selective TNF-α converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-α release. J. Med. Chem. 44 (2001) 3351-3354
66. Rabinowitz M.H., Andrews R.C., Becherer J.D., Bickett D.M., Bubacz D.G., Conway J.G., et al. Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE). J. Med. Chem. 44 (2001) 4252-4267
67. Duan J.J., Chen L., Wasserman Z.R., Lu Z., Liu R.Q., Covington M.B., et al. Discovery of γ-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor-α converting enzyme: Design, synthesis, and structure-activity relationships. J. Med. Chem. 45 (2002) 4954-4957
68. Xue C.B., Voss M.E., Nelson D.J., Duan J.J., Cherney R.J., Jacobson I.C., et al. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor-α release in vitro and in vivo. J. Med. Chem. 44 (2001) 2636-2660
69. Levin J.I., Chen J.M., Du M.T., Nelson F.C., Killar L.M., Skala S., et al. Anthranilate sulfonamide hydroxamate TACE inhibitors: II. SAR of the acetylenic P1' group. Bioorg. Med. Chem. Lett. 12 (2002) 1199-1202
70. Nelson F.C., de los Santos E., Levin J.I., Chen J.M., Skotnicki J.S., and DiJoseph J.F. Benzodiazepine inhibitors of the MMPs and TACE. Bioorg. Med. Chem. Lett. 12 (2002) 2867-2870
71. Musso D.L., Andersen M.W., Andrews R.C., Austin R., Beaudet E.J., Becherer J.D., et al. N -Hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: Oral activity via P1′ isobutyl substitution. Bioorg. Med. Chem. Lett. 11 (2001) 2147-2151
72. Conway J.G., Andrews R.C., Beaudet B., Bickett D.M., Boncek V., Brodie T.A., et al. Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther. 298 (2001) 900-908
73. Thabet M.M., and Huzinga T.W. Drug evaluation: Apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr. Opin. Invest. Drugs 7 (2006) 1014-1019
74. Duan J.J., Chen L., Lu Z., Jiang B., Asakawa N., and Sheppeck J.E. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett. 17 (2007) 266-271
75. Bourgeois D., and Royant A. Advances in kinetic protein crystallography. Curr. Opin. Struct. Biol. 15 (2005) 538-547
76. Meilleur F., Myles D.A., and Blakeley M.P. Neutron Laue macromolecular crystallography. Eur. Biophys. J. 35 (2006) 611-620
77. Bourgeois D., Vallone B., Arcovito A., Sciara G., Schotte F., and Anfinrud P. Extended subnanosecond structural dynamics of myoglobin revealed by Laue crystallography. Proc. Natl. Acad. Sci. USA 103 (2006) 4924-4929
78. Bernado P., and Blackledge M. Local dynamic amplitudes on the protein backbone from dipolar couplings: Toward the elucidation of slower motions in biomolecules. J. Am. Chem. Soc. 126 (2004) 7760-7761
79. Tolman J.R., and Ruan K. NMR residual dipolar couplings as probes of biomolecular dynamics. Chem. Rev. 106 (2006) 1720-1736
80. Meiler J., Prompers J.J., Griesinger C., and Bruschweiler R. Model-free approach to the dynamic interpretation of residual dipolar couplings in globular proteins. J. Am. Chem. Soc. 123 (2001) 6098-6107
81. Bouvignies G., Bernado P., Meier S., Cho K., Grzesiek S., Bruschweiler R., et al. Identification of slow correlated motions in proteins using residual dipolar and hydrogen-bond scalar couplings. Proc. Natl. Acad. Sci. USA 102 (2005) 13885-13890
82. Bernado P., Blanchard L., Timmins P., Marion D., Ruigrok R.W., and Blackledge M. A structural model for unfolded proteins from residual dipolar couplings and small-angle X-ray scattering. Proc. Natl. Acad. Sci. USA 102 (2005) 17002-17007
83. Koch M.H., Vachette P., and Svergun D.I. Small-angle scattering: A view on the properties, structures, and structural changes of biological macromolecules in solution. Q. Rev. Biophys. 36 (2003) 147-227